Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 7/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | ME2 | P23368 | 1/20 | 0.38 |
| ▸ | ME1 | P48163 | 1/20 | 0.38 |
| ▸ | ME3 | Q16798 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5715736 | 0.90 | HRH3 (0.43) | TACR3PANK3PKMHRH3 | |
| SCHEMBL5715522 | 0.89 | HRH3 (0.44) | TACR3PANK3PKMME2ME1 | |
| SCHEMBL5715552 | 0.88 | HRH3 (0.44) | PANK3HRH3 | |
| SCHEMBL5904386 | 0.86 | SMN1; SMN2 (0.55) | HRH3MAPT | |
| SCHEMBL5714761 | 0.86 | ALDH1A1 (0.46) | — | |
| SCHEMBL5904310 | 0.85 | AOC3 (0.40) | PANK3ME2ME1ME3HRH3 | |
| SCHEMBL5714563 | 0.83 | ME2 (0.43) | TACR3PANK3ME2ME1ME3 | |
| SCHEMBL5715146 | 0.82 | HTR3E (0.38) | PKMRECQL | |
| SCHEMBL5649776 | 0.82 | PKM (0.42) | PKMMAPT | |
| SCHEMBL5714872 | 0.81 | TACR3 (0.41) | TACR3PANK3SCN9AME2ME1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636189-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111007-A1 | 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160819-A1 | Substitued piperazine carbamates | LIPE, PNLIP, LIPC | TACR3 2445/4885PANK3 1247/4885PKM 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.